Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.